Important positive changes in Halozyme Therapeutics Inc (NASDAQ: HALO) investment behavior have recently occurred: its shorter term price trend turned up.
Significant positive changes in Halozyme Therapeutics Inc (NASDAQ: HALO) fundamentals have recently occurred: the stock’s power rating rose above 70, the consensus estimate for December, 2023 increased significantly, and significant quarterly earnings acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of A. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, HALO is expected to continue to be a major Value Builder.
Halozyme Therapeutics has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Halozyme Therapeutics has a good Power Rating of 76 and a very high Appreciation Score of 97, resulting in the Highest Value Trend Rating.
Recent Price Action
Halozyme Therapeutics Inc (NASDAQ: HALO) stock rose slightly by 0.2% on 12/6/23. The stock closed at $39.97. This advance was accompanied by normal trading volume. The stock has been strong relative to the market over the last nine months and has risen 0.7% during the last week.
Be the first to comment